1. Home
  2. TSSI vs SGMT Comparison

TSSI vs SGMT Comparison

Compare TSSI & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TSS Inc.

TSSI

TSS Inc.

HOLD

Current Price

$11.17

Market Cap

252.1M

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$6.35

Market Cap

204.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
TSSI
SGMT
Founded
2004
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
252.1M
204.2M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
TSSI
SGMT
Price
$11.17
$6.35
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$29.71
AVG Volume (30 Days)
1.4M
504.2K
Earning Date
11-13-2025
03-11-2026
Dividend Yield
N/A
N/A
EPS Growth
7.63
N/A
EPS
0.19
N/A
Revenue
$234,837,000.00
N/A
Revenue This Year
$54.04
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$60.59
N/A
Revenue Growth
91.66
N/A
52 Week Low
$5.63
$1.73
52 Week High
$31.94
$11.41

Technical Indicators

Market Signals
Indicator
TSSI
SGMT
Relative Strength Index (RSI) 61.87 53.90
Support Level $10.03 $5.95
Resistance Level $12.71 $6.42
Average True Range (ATR) 0.98 0.31
MACD 0.44 0.09
Stochastic Oscillator 71.21 77.04

Price Performance

Historical Comparison
TSSI
SGMT

About TSSI TSS Inc.

TSS Inc provides various services for planning, design, development, and maintenance of mission-critical facilities and information infrastructure, as well as integration services. Its services consist of technology consulting, design and engineering, project management, systems integration, systems installation, facilities management, and IT procurement services. The activities are organized into two segments: Procurement, Systems Integration, and Facilities Management. It generates the majority of its revenue from the Procurement segment.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: